Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

808P - Postoperative adjuvant radiotherapy can reduce the local recurrence of nasal cavity and paranasal sinus mucosal melanoma: A prospective design, retrospective analysis and case–control study

Date

10 Sep 2022

Session

Poster session 03

Topics

Therapy

Tumour Site

Melanoma

Presenters

Bin Lian

Citation

Annals of Oncology (2022) 33 (suppl_7): S356-S409. 10.1016/annonc/annonc1059

Authors

B. Lian1, Y. Yang1, L. Si1, L. Zhou1, Z. Chi1, X. Sheng1, L. Mao1, X. Wang1, C. Cui1, B. Zheng2, J. Guo1

Author affiliations

  • 1 Renal & Melanoma Dept, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN
  • 2 Radiotherapy Dept, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 808P

Background

Mucosal melanoma of the nasal cavity and paranasal sinuses (NPMM) is a highly aggressive disease. The role of postoperative adjuvant radiotherapy is controversial.

Methods

A database was prospectively designed for NPMM from Peking University Cancer Hospital. 300 patients between March 2009 and January 2020 were included and divided into SA (surgery alone, 158 patients) and SR group (surgery plus radiotherapy, 142 patients). Similarly and balanced system therapies were added into two groups. Postoperative radiotherapy was recommended, with a total dose of 65-70 Gy/30-35 fx to GTV and 60 Gy/30 Fx to CTV. The primary endpoint was relapse-free survival (RFS). The secondary endpoints included recurrence-free survival, distant metastasis-free survival (DMFS), and overall survival (OS).

Results

At a median follow-up of 50.0 months, The RFS in SA and SR groups were 9.8 and 15.2 months (HR: 0.714, 95% CI: 0.546-0.933, P = 0.014). The DMFS in SA and SR groups were 23.8 and 21.3 months (HR: 0.896, 95% CI: 15.7-31.9 vs. 13.3-29.3, P = 0.457). The OS in SA and SR groups was 31.0 and 35.1 months (HR: 0.816, 95% CI: 25.7-36.3 vs. 27.1-43.2, P = 0.178). For stage IVA patients, radiotherapy reduced the incidence of relapse by 0.43-fold with NPMM. For patients without adjuvant system therapy, radiotherapy reduced the incidence of recurrence by 0.85 times. Most adverse events were grade 1-2 and manageable.

Conclusions

Postoperative radiotherapy played a crucial role in the local control of NPMM, especially for patients with a local excision, observation only, T4a or IVA stages.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Peking University Cancer Hospital and Institute.

Funding

National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals Incubating Program, Beijing Municipal Administration of Hospitals’ Youth Programme.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.